Texas-based biotechnology firm Cassava Sciences has halted an advanced clinical trial for the experimental Alzheimer's drug simufilam after it failed to significantly reduce cognitive decline in people with mild to moderate Alzheimer's disease. According to the New York Times, the canceled trial comes after several foundational studies to support the drug were found to contain fraudulent data and subsequently retracted from scientific journals. Cassava Sciences was also forced to settle with the Securities and Exchange Commission in September over allegations of misleading statements about earlier trial results.
Related Posts
Engineers develop early-warning system for asthma
Engineers have developed a technology that’s showing promise as an early warning system for asthma attacks. Referred to as a disposable respiration…
Joyful Easter: He is risen!
Christians around the world will be celebrating the most important event of the church year on April 9: Easter Sunday, the Christian Passover. They…
ADHD associated with reduced life expectancy
A new study published in the British Journal of Psychiatry found that adults with attention deficit hyperactivity disorder, or ADHD, die an average of…